

KYS202002A

CD38

2023 1 11

2023 6 27

www.sse.com.cn

KYS202002A

2023-003

KYS202002A

FDA

2023-025

I

	KYS202002A
	CXSL2300396
	2023LP01631

2023

6 6

KYS202002A

KYS202002A

T B

CD38

8,581

2020

780

103

2020

16

2025

65

2020-2025

32.8%

2021

4

20%

2030

34

2025

6

Anifrolumab

GSK

2022

2022

11.46

31%

688331.SH 2022

2022

49.09

1780.51%

